Home

Projít Banyán Pes median overall survival negativní By měl vertikální

Evidence for improved survival with bevacizumab treatment in recurrent  high-grade gliomas: a retrospective study with (“pseudo-randomized”)  treatment allocation by the health insurance provider | SpringerLink
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink

Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for  Inoperable, Locally Advanced Pancreatic Cancer with
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with

Revlimid Dex Median Overall Survival In Non-transplant - Overall Survival -  Free Transparent PNG Download - PNGkey
Revlimid Dex Median Overall Survival In Non-transplant - Overall Survival - Free Transparent PNG Download - PNGkey

Quality improvement program in radiation oncology: understanding patient  hospitalizations, treatment breaks, and weight loss in patients receiving  radiotherapy | Radiation Oncology | Full Text
Quality improvement program in radiation oncology: understanding patient hospitalizations, treatment breaks, and weight loss in patients receiving radiotherapy | Radiation Oncology | Full Text

Trends in glioblastoma: outcomes over time and type of intervention: a  systematic evidence based analysis | SpringerLink
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink

Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC

Overall survival of patients with metastatic breast cancer in Sweden: a  nationwide study | British Journal of Cancer
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer

NEJM on Twitter:
NEJM on Twitter: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months

View Image
View Image

View Image
View Image

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer  | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM

Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

survival - Time to event analysis - median (IQR) is <75% experience event -  Cross Validated
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated

Median overall survival (mOS) and median progression-free survival... |  Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram

Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who  Underwent Conversion Surgery | Anticancer Research
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research

Kaplan-Meier curves for overall survival. The median overall survival... |  Download Scientific Diagram
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram

Cancers | Free Full-Text | Identification of Predictive Factors for Overall  Survival and Response during Hypomethylating Treatment in Very Elderly  (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life  Experience
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Acute lymphoblastic leukemia: A population‐based study of outcome in the  United States based on the surveillance, epidemiology, and end results  (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology  - Wiley Online Library
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library

View Image
View Image

View Image
View Image

Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of  Various Parameters in Patients with 1-12 Brain Metastases
Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases

Disparities in Care and Outcomes
Disparities in Care and Outcomes

Overall survival of patients with metastatic breast cancer in Sweden: a  nationwide study | British Journal of Cancer
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer

Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... |  Download Scientific Diagram
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram

Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)